Registration for all lectures in the series on Health and Life-Sciences Entrepreneurship
Sales Ended
Registration for all lectures in the series on Health and Life-Sciences Entrepreneurship

Registration for all lectures in the series on Health and Life-Sciences Ent...

Event Information

Share this event

Date and Time

Location

Location

Lecture Theatre 1/2

John Radcliffe Hospital, Headley Way

Oxford

OX3 9DU

United Kingdom

View Map

Friends Who Are Going
Event description

Description

Are you interested in innovation? Are you already an established entrepreneur thinking about translating your research idea into a successful business? Or do you simply want to gain insights into the commercial potential of your work? Innovation Forum Oxford, in collaboration with MRC Weatherall Institute of Molecular Medicine is providing a course of free workshops for scientists, entrepreneurs, clinicians and other NHS workers delivered by expert speakers. These will equip you to take any idea from development through to a successful company. Each workshop will be accompanied by networking opportunities.

Where: Lecture Theatre 1, John Radcliffe Hospital, Oxford
When: 18:00/18:30

Lecture 1 (12th Oct 2016, Wed, 18:30)
Innovation in Oxfordshire and trends shaping the industry

Professor Sir John Bell GBE, FRS


Lecture 2 (24th Oct 2016, Mon, 18:00)
How to develop commercial ideas from research

Torsten Reil, CEO – NaturalMotion

Professor Andrew Carr, NIHR Senior Investigator and a Fellow of the Academy of Medical Sciences

Professor Tom Brown, Professor of Nucleic Acid Chemistry - University of Oxford

Lecture 3 (9th Nov 2016, Wed)
How to explore business tools to develop and evaluate your idea - Lean Canvas

Maria Nikolou, Senior Programme Manager - the Entrepreneurship Centre

Dr Les Russell, Chief Executive Officer - OrganOx Limited

Lecture 4 (30th Nov 2016, Wed)
How to define your target market

Neil Butler, CEO - Spectromics

Lecture 5 (January 2017, date TBC)
How to protect your idea and when to ask for advice

Nicola McConville, Partner - Penningtons Manches

Sue Staunton, Business services partner - James Cowper Kreston


Dr Philip Webber, European Patent Attorney - Dehns Patent & Trade Mark Attorneys

Lecture 6 (18th Jan 2017, Wed)
Finance for Scientists

Lecture 7 (1st Feb 2017, Wed)
How to write a business plan

Professor Peter Dobson OBE


Lecture 8 (15th Feb 2017, Wed)
How to give an effective pitch

Lecture 9 (1st Mar 2017, Wed)
How to negotiate

Lecture 10 (15th Mar 2017, Wed)
How to raise capital: From who and from where?

Andrew McClean, Lead Life Sciences Investor - Oxford Sciences Innovation


Dr Mike Stein, CEO - OxStem

Lecture 11 (29th Mar 2017, Wed)
How to effectively market your idea

Lecture 12 (26th Apr 2017, Wed)
Spinning out your research

Lecture 13 (10th May 2017, Wed)
Support for innovators

Dr Victor Bolanos-Garcia, Knowledge Exchange and Impact Faculty Lead - Oxford Brookes University


Register for individual talks or the whole series to receive a Certificate of attendance*.

* Participants who attend 11 out of 13 lectures will receive a Certificate of attendance.




SPEAKERS BIOGRAPHY:

Professor Sir John Bell GBE, FRS

Professor Sir John Bell GBE, FRS is Regius Professor of Medicine at Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research. He served as President of the Academy of Medical Sciences from 2006 to 2011. As a Rhodes Scholar (1975-78), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987. His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics. In 2001, he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board which he has chaired since 2012. Sir John was responsible for the working party that produced the highly influential Academy of Medical Sciences “Strengthening Clinical Research” report that highlighted the need for the UK to focus some of its attention on developing expertise in translational research. In December 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister. He sits on the board of Genome England Limited and chairs its Science Advisory Committee. He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry.

Torsten Reil, CEO – NaturalMotion

Torsten Reil, CEO – NaturalMotion holds a BA in Biology from Oxford University and an MSc in Evolutionary and Adaptive Systems from Sussex University. Prior to founding NaturalMotion, Torsten was researching for a PhD in Complex Systems at Oxford University’s Zoology department, from which he spun off NaturalMotion. Torsten has been named amongst MIT’s TR100 global top innovators, and has spoken and TED, TED Global, Google Zeitgeist and the Apple iPhone 5 keynote.

Professor Andrew Carr, NIHR Senior Investigator and a Fellow of the Academy of Medical Sciences

Professor Andrew Carr is an NIHR Senior Investigator and a Fellow of the Academy of Medical Sciences. He is the Nuffield Professor of Orthopaedic Surgery, Head of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (from 2001) and an honorary consultant trauma and orthopaedic surgeon at the Oxford University Hospitals NHS Foundation Trust (from 1993).

He is director of the NIHR Oxford Musculoskeletal BRU (2008-) and was a non-executive director of the Nuffield Orthopaedic Centre (NOC) NHS Trust (2001-2011). He was divisional director of clinical services from 2011-2013 and led the NOC during its merger to form Oxford University Hospital NHS foundation Trust. He co-founded the Royal College of Surgeons Trial Unit in Oxford in 2012.

Professor Carr has made important contributions to improving the quality and outcome of surgery. He has published over 300 peer reviewed articles in journals including the Lancet, the BMJ and Science Translational Medicine. He is one of the most highly cited orthopaedic academics globally. He founded the Botnar Research Centre in 2002 and led the relocation of the Kennedy Institute for Rheumatology to Oxford in 2011 (a total capital investment of over £75M). The multidisciplinary department has grown under his leadership from 20 staff in 2001 to over 450 staff and 95 postgraduate students in 2016.

He has pioneered the use of large scale surgical randomised controlled trials, this includes defining the indications for, and ethics of placebo, or sham surgery, controls in surgical trials. He has also led the involvement of patients in assessing the outcome of orthopaedic surgery with the development of the Oxford Scores. Used to predict and detect early failure of poorly performing surgical interventions they have been adopted by health providers and regulators worldwide, leading to policy and treatment guideline changes and significant improvements in the quality of life of patients.

Professor Carr’s research into mechanisms of soft tissue inflammation, repair and fibrosis has led to the invention of novel electrospun nanofibre tissue engineering implants which aim to enhance endogenous tissue repair using biophysical cues. These implants are now entering first in man clinical trials funded by the Wellcome Trust Health Innovation Challenge Fund (HICF) and the NIHR i4i programme.

Professor Tom Brown, Professor of Nucleic Acid Chemistry - University of Oxford

Tom Brown was formerly Professor of Chemistry at Edinburgh University and Southampton University and is currently Professor of Nucleic Acid Chemistry at Oxford University. He is a member of the Departments of Chemistry and Oncology. His research interests centre on DNA sequence recognition and applications of oligonucleotide chemistry in biology and medicine. He is the co-founder of three Biotech companies (Oswel, ATDBio and Primer Design) and has published over 350 research papers and patents. He has received several awards including the Royal Society of Chemistry (RSC) Josef Loschmidt prize, the RSC award for Nucleic Acid Chemistry and the RSC prize for Interdisciplinary Research. He was Chemistry World entrepreneur of the year for 2014 and BBSRC Commercial Innovator of the Year and overall Innovator of the Year for 2016. Recently he was presented with a lifetime award for external engagement and promoting impact by Oxford University. Tom is a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Chemistry. He is President of the Chemistry Biology Interface Division of the RSC and Editor-in-Chief of the RSC Book series on Chemical Biology. He is currently Associate Head of the Chemistry Department at Oxford with responsibility for Research.

Maria Nikolou, Senior Programme Manager - the Entrepreneurship Centre

Maria Nikolou is the Senior Programme Manager at the Entrepreneurship Centre where she develops and delivers new programmes related to Entrepreneurship. In 2012, she established a seed fund investment scheme, Oxford Seed Fund, for the Entrepreneurship Centre which she currently directs and chairs the Advisory Board. The Seed Fund programme is aimed at early stage ventures from Oxford University students, staff and alumni. She’s also involved with curriculum courses related to entrepreneurship designed for business and engineering students. Finally, she is a board member at VentureFest that runs an annual event focused on SMEs.

A scientist by training with a cross over to business, Maria is interested in supporting global innovative solutions for both commercial and social challenges. Maria holds an MBA (London, UK) and a PhD in Physics (US). She has worked as a Post-Doctoral Associate in Materials, Science and Engineering at Cornell University, NY and has international experience working in both academia and industry.

Dr Les Russell, Chief Executive Officer - OrganOx Limited

Les has been CEO of OrganOx since its formation in 2008. He holds first class honours and PhD degrees in Chemistry from the University of London and has extensive experience in the medical devices industry. Early in his career he worked in R&D with Ciba Corning developing sensor technologies for blood analysis before moving into business development, marketing and general management roles with early stage and multi-national corporations including Byk Gulden and Baxter. He also has experience of leading smaller companies through institutional fund-raisings, an IPO on AIM, an acquisition and securing additional funds from institutional investors.

Les has led OrganOx through 5 funding rounds and development of the OrganOx metra normothermic liver perfusion device from laboratory bench to pivotal clinical studies and full commercialisation and helped secure 3 grants for additional clinical studies and further development.

Neil Butler, CEO - Spectromics

The majority of my career has involved managing technology businesses, with the past 17 years focused on medical diagnostics within young entrepreneurial companies. My executive career in diagnostics focused on taking conceptual technologies through to companies ready for commercial sales and investor exit. For the past 5 years I have devoted most of my time to non-executive board positions of young diagnostic companies.
I have worked on a full spectrum of analytical technologies including immunochemistry, electrochemistry, nucleic acid, cell counting, single cell analysis and sequencing. A majority of the diagnostic businesses that I have led have been involved with near-patient testing or portable systems suited to use in decentralised settings, rather than for high throughput laboratory testing. This has involved building an understanding of the regulatory approach as well as the clinical pathways and healthcare economics. Relationships have been established with many of the large IVD companies.
I have personally been involved with raising $100m over about 10 financing rounds from European / US investors. Also I have had experience from the VC side of transactions with recent investment due diligence assignments for Novartis Ventures and other VC’s.
My earlier career was spent in large corporates involving polymers and semi-finished products used in medical devices / electronics involving management positions including production, product management, sales and marketing.

Nicola McConville, Partner - Penningtons Manches

Nicola is a partner at law firm Penningtons Manches and advises technology companies on all aspects of corporate law including the delivery of funding rounds and strategies for growth and realisation of value. She has acted for numerous companies from early stage through to major institutional funding rounds, strategic acquisitions and exit via sale or IPO. Her clients include organisations in the life sciences, digital and clean tech sectors, many of which have an international dynamic to their business. She has advised over 40 spin out and start-ups companies from Oxford University as well as several more from other institutions.

Nicola is recognised by both Chambers UK and The Legal 500, winning praise for coming up with ‘simple but effective solutions to complex legal issues’ and for being ‘absolutely charming and very competent’. She has also been described by clients in the directories as being ‘absolutely passionate about her job’ and as having ‘a palpable determination to drive change that is a pleasure to witness’.

Sue Staunton, Business services partner - James Cowper Kreston

Sue Staunton is a business services partner for accountants and business advisers, James Cowper Kreston, based in their Oxford office. Sue heads the firm's technology team which advises clients of all sizes from spin out to IPO and beyond.

Sue works with clients on the development and implementation of their corporate strategies. She also has a great deal of experience in working with businesses in financial crisis to establish strategies to assist them to move forward successfully.

Sue has been involved in running a number of businesses so understands what it can be like at the sharp end!

James Cowper Kreston is one of the leading firms of accountants and business advisers in the Thames Valley and South of England, with over 200 Partners and staff operating from six offices. The firm has a strong international capability through its membership of Kreston International, the 13th largest accounting association in the World.

Dr. Philip Webber, European Patent Attorney - Dehns Patent & Trade Mark Attorneys

Philip is a European patent attorney with nearly 25 years’ experience of working with patents in the biotech and pharma fields.

His first degree was in genetics from Cambridge University (UK); he then carried out research in molecular biology and received his PhD from Warwick University (UK). He qualified as a UK and European Patent Attorney with Dehns (formerly Frank B. Dehn & Co.) and is now a partner in their Oxford Life Sciences Group.

Philip writes and deals with patent applications in all areas of molecular biology and biochemistry including genomics, proteomics, recombinant DNA and protein products, transgenic plants and animals, diagnostics assays, virology and vaccines. He has particular expertise in patenting antibodies, stem cells and CRISPR-based inventions.

Philip works mainly with SMEs and universities by obtaining patent protection for their inventions and advising them on their IP strategies.

He is an active member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA). He has spoken at over 100 conferences, and on BBC Radio 4 on the patenting of inventions, as well as publishing a number of papers in this area.

Professor Peter Dobson OBE

Professor Peter J Dobson OBE, BSc, MA (Oxon), PhD, C Phys, F Inst P, Member of the ACS, FRCS. (The Queen’s College, Oxford)

Peter has had a broad career covering a wide range of disciplines from physics and chemistry to materials science and engineering. He has also worked in industry (Philips) as well as academia (Imperial College and Oxford) and was responsible for creating and building The Begbroke Science Park for Oxford University. He has published over 180 papers and 30 patents. He has founded 3 companies and advised on the formation of 8 more. He was (2009-2013) the Strategic Advisor on Nanotechnology to the Research Councils in the UK and sits on several EPSRC panels and committees. Peter sits on the EPSRC Strategic Advisory Board on Quantum Technology. He was awarded the OBE in 2013 in recognition of his contributions to science and engineering. He is currently a Principal Fellow at Warwick Manufacturing Group, Visiting Professor at King’s College London and also has part-time positions at UCL and Bristol University. Peter delivers courses at Graduate level in the areas of biosensors, nanotechnology, innovation, entrepreneurship and related topics and advises on innovation.

Andrew McClean, Lead Life Sciences Investor - Oxford Sciences Innovation

Andrew McLean is the lead life sciences investor for Oxford Sciences Innovation. OSI is a £350 million company investing in the most exciting start-ups built on world-leading Oxford science. Prior to joining OSI Andrew consulted in the pharmaceutical & biotech practice at McKinsey. Andrew is a physician by training, studied philosophy, politics & economics at Christ Church in Oxford and his work background includes stints in wine shops, hospitals & Goldman Sachs.

Dr Mike Stein, CEO - OxStem

Dr. Michael Stein is a serial entrepreneur, medical scientist, business executive and strategic advisor with senior experience in healthcare, drug discovery, therapeutics, media and software industries. Dr. Stein is passionate about healthcare and the environment and trained in financial risk management. A dynamic team builder with natural instincts for leadership and communication, he is highly skilled in business development at the highest levels of government and corporate enterprise. Has inspired and built several successful internet and healthcare businesses, and able to support development, growth and strategic advice for early stage companies or spinouts from Universities or larger corporations.

Dr. Michael Stein is the current Chairman and CEO of both OxStem Ltd. and Province Tx (Oy). Oxstem is a drug discovery company targeting stem and progenitor cells which was recently spun out of the University of Oxford. Michael will continue as CEO at OxStem having raised a £16.9m series A (a UK record for a university spin-out), until he has found his successor (in process). ProVince Tx, a spin-out company from the University of Helsinki, is a developer of novel vaccination-based cancer therapies. Its unique approach to immunotherapy in cancer combines an oncolytic virus with tumour specific peptides, for a rapidly adaptable and long lasting cancer vaccination. In 2001, he co-founded the Map of Medicine Ltd (the Map) with University College London. The Map was nationally licensed across NHS England in 2005 and is primarily used by commissioners for planning healthcare services across the continuum of care. The Map was acquired by Hearst Business Media (HBM) in 2008, and Michael transitioned as executive vice-president (healthcare innovation) to HBM until 2011. Since 2011, Michael has assisted a number of start-up businesses, notably serving as the founding CEO and executive chairman for Doctor Care Anywhere, acquired by Synergix in 2015. Michael graduated as a medical doctor (Honours) and biochemist (First Class Honours) from the University of Cape Town (1988) and from the University of Oxford (Rhodes Scholar) with a doctorate in physiological sciences (Immunology). He subsequently was appointed as a Junior Research Fellow in Medicine at Trinity College, Oxford (1992-95).

Dr Victor Bolanos-Garcia, Knowledge Exchange and Impact Faculty Lead - Oxford Brookes University

Dr Victor Bolanos-Garcia is Senior Lecturer in Clinical Biochemistry, Knowledge Exchange and Impact Faculty Lead and member of the management team of the BioInnovation hub at Oxford Brookes University. He represents Oxford Brookes at the Oxford Academic Health Science Centre (OxAHSC), a new partnership with Oxford Health NHS Foundation Trust, Oxford University Hospitals NHS Trust, and the University of Oxford that combines the institutions’ individual strengths in basic science, translational research and clinical expertise to address 21st century healthcare challenges thus contributing to drive economic growth. He is also a member of the iCASE committee of the Doctoral Training Programme (DTP) funded by the BBSRC and run in partnership with The University of Oxford, The Pirbright Institute, Diamond Light Source (DLS), STFC Central Laser Facility and the ISIS Neutron Source.

Dr Bolanos-Garcia is a structural biologist who trained with Francisco Bolívar-Zapata (the creator of the plasmid pBR322, one of the first widely used E. coli cloning vectors) at the National Autonomous University of Mexico (UNAM), Ermanno Gherardi at the Laboratory of Molecular Biology of the Medical Research Council (LMB-MRC) and Prof. Sir Tom Blundell at the University of Cambridge. As a Wellcome Trust International Research Fellow, Bolanos-Garcia studied the mechanisms of cell proliferation and motility by the MET kinase receptor and initiated work on the spindle assembly checkpoint (SAC), the mechanism that ensures the accurate separation of the genetic material to an offspring every time a cell divides. Study of the SAC in the Bolanos-Garcia lab follows a multidisciplinary approach that combines X-ray protein crystallography, protein biochemistry and protein biophysics with chemioinformatics, molecular and cellular biology methods. As well as conducting basic research, Dr Bolanos-Garcia leads a programme of science directed towards improvements in human health through the development of innovative diagnosis and therapeutic approaches to tackle cancer, birth and development disorders resulting from chromosome separation defects.


IN COLLABORATION WITH:

SUPPORTED BY:



INNOVATION FORUM PARTNERS:



INNOVATION FORUM OXFORD LOCAL PARTNERS:



About the Innovation Forum

The Innovation Forum seeks to promote innovation by building bridges between academia, industry and government and linking innovative minds across disciplines. They are a global network of researchers and entrepreneurs active at the Universities of Cambridge, Oxford, London, Edinburgh, Copenhagen, Lausanne, Barcelona, Hong Kong and Tokyo. For more information, please visit: www.inno-forum.org

Share with friends

Date and Time

Location

Lecture Theatre 1/2

John Radcliffe Hospital, Headley Way

Oxford

OX3 9DU

United Kingdom

View Map

Save This Event

Event Saved